Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. Skin cancer is now a leading cause of illness and disfigurement after kidney, liver, heart, and lung transplantation. Given the increased risk and burden of skin cancer in transplant recipients, prevention is critical. Nicotinamide is a form of Vitamin B3 that has been shown to protect against skin cancer in the general population. However, it is unclear whether nicotinamide is effective among immune-suppressed transplant recipients. Investigators will conduct a clinical trial involving multiple transplant centres in Canada to evaluate whether oral nicotinamide (500 mg twice daily) is effective and safe for preventing skin cancer. Investigators will recruit 396 high-risk adult kidney, liver, heart, and lung transplant patients who have previously had at least one skin cancer. Patients will receive nicotinamide or sham tablets for up to 4 years. The results will inform efforts to improve the long-term health of transplant recipients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Przeszczep nerki, wątroby, serca lub płuca przeprowadzony co najmniej 2 lata temu
- •Co najmniej jeden potwierdzony nowotwór skóry w przeszłości
- •Obecnie przyjmowanie leków przeciwko odrzuceniu przeszczepu (kalcyneuryny inhibitory)
- •Możliwość uczestniczenia w wizytach kontrolnych
✗ Disqualifies
- •Przyjmowanie nikotynamidu lub niacyny w wysokich dawkach w ciągu ostatnich 12 tygodni
- •Nyleczony rak skóry w momencie rozpoczęcia badania
- •Odrzucenie przeszczepu w ciągu ostatnich 12 tygodni
- •Ciężka choroba wątroby lub nerek
- •Inne typy nowotworów w ciągu ostatnich 5 lat (oprócz badanego raka skóry)
- •Ciąża lub karmienie piersią
- •Alergia na nikotynamid
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
University of Calgary
Calgary, Canada
University of Alberta
Edmonton, Canada
Vancouver General Hospital
Vancouver, Canada
St. Paul's Hospital
Vancouver, Canada
The Ottawa Hospital
Ottawa, Canada
Toronto General Hospital
Toronto, Canada
Women's College Hospital
Toronto, Canada
Trial contact
Stephanie Jewell, BSc. Hons
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.